Because CHC Group Ltd (NYSE:HELI) has experienced a fall in interest from hedge fund managers, it’s safe to say that there exists a select few funds who were dropping their positions entirely heading into Q4. Intriguingly, Thomas Steyer’s Farallon Capital said goodbye to the biggest position of the 700 funds watched by Insider Monkey, comprising an estimated $0.2 million in stock. Benjamin A. Smith’s fund, Laurion Capital Management, also dumped its stock, about $0.1 million worth. These moves are intriguing to say the least, as aggregate hedge fund interest fell by 6 funds heading into Q4.
Let’s now review hedge fund activity in other stocks similar to CHC Group Ltd (NYSE:HELI). These stocks are Eleven Biotherapeutics Inc (NASDAQ:EBIO), Zosano Pharma Corp (NASDAQ:ZSAN), Network-1 Technologies Inc (NYSEMKT:NTIP), and Ambassadors Group, Inc. (OTCMKTS:EPAX). All of these stocks’ market caps match HELI’s market cap.
|Ticker||No of HFs with positions||Total Value of HF Positions (x1000)||Change in HF Position|
As you can see these stocks had an average of 5 hedge funds with bullish positions and the average amount invested in these stocks was $5 million. That figure was $3 million in HELI’s case. Zosano Pharma Corp (NASDAQ:ZSAN) is the most popular stock in this table with five funds holding shares, while Eleven Biotherapeutics Inc (NASDAQ:EBIO) is the least popular one. Compared to these stocks CHC Group Ltd (NYSE:HELI) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.